Internal Medicine

Patients who demonstrated high trough concentrations early on in treatment were more likely to achieve remission by weeks 14 or 52.

Subcutaneous administration of the gut-selective treatment was notably well-tolerated, safe, and cost-effective.

NAFLD is currently the most prevalent liver disease in the US.

An analysis of data from the KORA study suggests HSV 2 and CMV seropositivity were independently associated with increased odds of developing prediabetes.

An analysis of data from more than 3500 individuals followed for more than 20 years provides insight into the impact of food insecurity on risk of cardiometabolic conditions, including obesity and type 2 diabetes.

Investigators observed a potential risk between Black individuals with baseline signs of dehydration, SCT and related mortality over 30 years.

The daily oral combination therapy will be reconsidered for treating endometriosis pain this August.

The Massachusetts General Hospital investigator discusses how LVADs and mechanical circulatory supports have altered the national heart donor strategy.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Data from a study presented at the European Congress on Obesity details the effects of adherence to a vegan diet on cardiometabolic health using data obtained from randomized controlled trials assessing the effects of vegan diets as an intervention.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.

Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.

A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.

New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.

A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.

An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

Nancy Holekamp, MD discusses the substantial emotional burden and impact on independence of GA reported in the Geographic Atrophy Insights Survey.